Insmed Inc. (NASDAQ:INSM)’s share price fell 1% on Tuesday . The stock traded as low as $13.08 and last traded at $13.31, with a volume of 93,724 shares trading hands. The stock had previously closed at $13.44.

A number of equities analysts recently commented on INSM shares. Zacks Investment Research raised shares of Insmed from a “sell” rating to a “hold” rating in a research report on Monday, May 2nd. Piper Jaffray Cos. set a $24.00 price target on shares of Insmed and gave the stock a “buy” rating in a research report on Sunday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Wednesday, June 15th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Insmed has a consensus rating of “Buy” and an average price target of $23.57.

The stock has a 50 day moving average price of $11.52 and a 200 day moving average price of $11.81. The stock’s market cap is $829.77 million.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.59) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.56) by $0.03. Analysts predict that Insmed Inc. will post ($2.25) EPS for the current fiscal year.

A hedge fund recently raised its stake in Insmed stock. Jennison Associates LLC increased its stake in shares of Insmed Inc. (NASDAQ:INSM) by 0.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,168,760 shares of the biopharmaceutical company’s stock after buying an additional 4,159 shares during the period. Jennison Associates LLC owned approximately 1.89% of Insmed worth $21,213,000 as of its most recent SEC filing.

Insmed Incorporated is a biopharmaceutical company. The Company operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases. The Company’s lead product candidate, ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for patients with nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that is capable of causing irreversible lung damage and can be fatal.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.